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INTRODUCTION 
Drug interactions are a major factor in the etiology of adverse 
drug reactions. Because patients often take mere than one medica-
tion, the possibility of a patient experiencing an adverse drug 
interaction Is of concern. Numerous drug interactions caused by 
cimetldine, a potent H^ receptor antagonist, have been documented in 
humans. Cimetidine has been shown to decrease the elimination of a 
2-4 5 
variety of drugs including, antipyrine , aminopyrine , chlordiaze-
poxide^'7, diazepam^ 1 0 , warfarin11 ^, theophylline^'1^ 2 1 , 
22 23 24 25 28 quinidine , carbamazepine , and phenytoin . All of the 
above mentioned drugs are eliminated after metabolism by mixed 
•function oxidases in the liver, suggesting that cimetidine inhibits 
the action of the cytochrome P-450 oxidative enzymes. 
Piroxlcam is a recently introduced non-steroidal anti-inflam-
matory drug (NSAID) belonging to a novel chemical group, the oxicams, 
Clinical studies indicate that piroxicam is safe and effective in 
long term management of rheumatoid arthritis, osteoarthritis, and 
29-33 
ankylosing spondylitis. The elimination half-life of piroxicam 
is prolonged: in pharmacokinetic studies, the mean half-life ranged 
34-4 
from 37.5 to 60.4 hours (range 14-158 hours) in healthy subjects. 
Despite this wide inter-individual range, the half-life within an 
37 
individual appears constant. 
Piroxicam is metabolized in man primarily by 5'-pyridine ring 
42 
hydroxylation followed by glucuronidation. The metabolites of 
piroxicam have little or no anti-inflammatory activity in animal 
43 
models. The metabolites have also been shown to be inactive as 
2 
inhibitors of cyclo-oxygenase in tissue preparations in which 
36 
piroxicam showed potent inhibitory activity. 
Since the main metabolic pathway of piroxicam is hydroxylation, 
a reaction generally dependent on the hepatic cytochrome system, 
piroxicam is potentially susceptible to interventions that alter 
liver metabolic activity such as concurrent cimetidine 
administration. 
In patients treated with piroxicam, the gastrointestinal system 
44-46 
appears to be the predominant site of adverse effects. These 
effects include epigastric and abdominal pain, nausea and vomiting, 
melena, hematemesis, and peptic ulcer. Because of the nature of the 
side effects, the concomitant use of cimetidine and piroxicam is 
likely. 
Depression of renal function has been associated with 
47 48 49-52 piroxicam ' and with other NSAIDs . Hemodynamic changes 
secondary to prostaglandin synthesis inhibition have been proposed as 
a mechanism for the depression in renal function observed with the 
52-55 
NSAIDs. Patients at risk are those with underlying intrinsic 
renal disease, with or without obvious renal insufficiency, and 
patients with decreased effective renal plasma flow due to such 
conditions as volume contraction, congestive heart failure, and liver 
disease with ascites. Additional risk factors include advanced age 
and concurrent use of diuretics.47"56 
Assuming that the hydroxylation of piroxicam is cytochrome P-450 
mediated, the addition of cimetidine to the therapeutic regimen of a 
patient on piroxicam could result in a decrease in piroxicam elimina-
tion and prolongation of its effect. Prolongation of the anti-
3 
prostaglandin effect is of clinical concern because it may increase 
the hazard of renal dysfunction in patients at risk. 
The purpose of this study was to determine if serum concentra-
tions of piroxicam following a single oral dose are altered by 
previous and concurrent administration of cimetidine. 
MATERIALS AND METHODS 
The protocol arid the consent form were approved by the University 
of Utah Institutional Review Board, 
Subject Selection 
Twelve healthy male volunteers consented in writing to partici-
pate in the study. Subjects were admitted to the study if 1) they 
had a normal clinical and laboratory examination, 2) they did not use 
tobacco, 3) their weight was within 25% of their ideal body weight, 
4) they had not used any medication or alcohol within the previous 2 
weeks, 5) they showed willingness and ability to perform the tasks 
necessary for the study. 
Subjects were excluded for the presence or history of hypersen-
sitivity to aspirin, piroxicam or cimetidine. No alcohol or medica-
tion was permitted during the study. 
Before entry into the study each subject underwent laboratory 
examination and clinical assessment including medical and medication 
histories and a physical examination. A copy of the consent form and 
of the form used to collect the clinical assessment data are included 
in Appendix 1. 
The laboratory examination included a complete blood count with 
differential and platelets, urinalysis, blood chemistry profile 
I.e., sodium, chloride, potassium, carbon dioxide, urea nitrogen, 
glucose, creatinine, uric acid, calcium, phosphate, total and direct 
bilirubin, total protein, albumin, cholesterol, gammaglutamyltrans-
ferase, alkaline phosphatase, lactic dehydrogenase, aspartate amino-
transferase, and alanine aminotransferase. 
5 
Study Plan 
The study was conducted at the University of Utah Hospital 
Rheumatology clinic. On the first day of the study, following an 
overnight fast, each subject received 20 mg of piroxicam (Feldene , 
Pfizer Laboratories; New York, NY) orally as a single dose with 180 
ml of water. Subjects ingested a standard breakfast one hour after 
the administration of piroxicam. Venous blood samples were collected 
according to the schedule described in the section sample collection. 
Subjects began urine collection in 24 hour aliquots for seven days 
following the piroxicam dose (see Sample Collection). 
On day 7, each subject received 56 tablets of cimetidine 300 mg 
/ ® 
(Tagamet , Smith Kline and French Laboratories; Philadelphia, PA) 
with instructions to take one tablet four times a day with meals and 
at bedtime for 14 days, starting on day 8 of the study. 
On day 15 of the study, seven days after the initiation of 
cimetidine, each subject, once again, received 20 mg of piroxicam 
orally. Blood and urine samples were collected in the same fashion 
as after the first dose. Cimetidine administration was continued 
throughout blood and urine collection. Figure 1 illustrates the 
study design. 
Subjects were interviewed for possible adverse reactions at 
least twice during the study period. Adverse reaction forms were 
completed by the investigator after each interview (see Appendix 2) . 
Subjects were asked to keep a record of compliance and adverse 
effects during cimetidine administration (see Appendix 3) . Compli-
ance was also assessed by interview and capsule count, both performed 
twice during the study period. 
6 
Sample Collection 
Venous blood samples were collected into red top Vacutainers 
(Vacutainer System, Rutherford, NJ) from an antecubital vein by 
venipuncture or through a cannula. The cannula used for the first 11 
to 12 samples was kept patent by the instillation of 2 ml of heparin 
(100 units/ml) after each blood draw or every hour whichever came 
first. Seven milliliter blood samples were collected at the follow-
ing times relative to piroxicam ingestion: 0, 0.5, 1, 1.5, 2, 2.5, 3, 
3.5, 4, 6, 9, 12, 24, 34, 48, 58, 72, 96 and 168 hours. 
The blood was allowed to clot and was then centrifuged at 3780 
rpra for six minutes. The serum was collected from each specimen and 
stored at -20°C pending analysis. 
Urine was collected into sterile plastic bags (Whirl-Pak , 
Nasco; Modesto, CA) or plastic containers in 24 hour aliquots for 
seven days after piroxicam dose. Urine was kept refrigerated until 
measurement. The total volume of each 24 hour period was pooled and 
measured daily. For each 24 hour aliquot, 60 ml sample was collected 
and stored at -20°C. Appendix 4 contains a copy of the blood and 
urine collection forms. 
Piroxicam Analysis 
The serum samples were analyzed for piroxicam concentration by 
high-performance liquid chromatography. The assay was performed by 
Pfizer Laboratories using the method of Twomey et al.57 The method 
sensitivity limit is 0.5 mcg/ml, A 5 meg/ml control sample which was 
run with each assay showed a standard deviation of 0.2 mcg/ml and a 
coefficient of variation of 4.7 percent. Cimetidine does not inter-
58 
fere with the piroxicam assay. 
Pharmacokinetic Description and Calculation 
For each subject, the elimination rate constant (kel), half-life 
(tl/2), and area under the serum concentration versus time curve 
(AUC) were calculated using piroxicam concentrations obtained before 
and after cimetidine administration. The equations used to obtain 
these parameters are included in Appendix 5. 
The piroxicam serum concentration-time data were plotted on 
semi-logarithmic graph paper. The elimination rate constant (kel) 
was obtained from least squares regression of the data points between 
the 12 hour concentration and the last measurable serum concentration. 
The half-life was calculated from the elimination rate constant. 
The area under the curve was calculated using the trapezoidal 
59 
method. As recommended by Chiou, the linear trapezoidal method was 
used for pre-peak and plateau data and the logarithmic trapezoidal 
method was used for the post-peak or post-plateau data. The remain-
ing area from the last measurable point to infinity was calculated by 
dividing the concentration at the last time point by kel. The total 
area was the sum of the results of these three determinations. 
Statistical Analysis 
Due to the small sample size, a nonparametric test was used to 
analyze the pharmacokinetic changes. The Wilcoxon matched-pairs 
signed-ranks two-tailed test with an alpha level of 0.05 for 
significance was chosen. 
8 
RESULTS 
Of the twelve healthy male volunteers admitted to the study, ten 
completed the study. The mean age was 27 years with a range of 23 to 
35 years. The mean weight was 79.7 kilograms, and ranged from 65.9 
to 100 kilograms. One volunteer (#010) suffered from a cold and was 
excluded because he had to use medications. Another volunteer (#012) 
discontinued the study because he did not tolerate the venipunctures. 
The piroxicam plasma concentration-time profiles with and 
without cimetidine treatment are illustrated for each volunteer in 
Figures 2 to 11. The calculated elimination rate constants (kel) and 
half-lives (tl/2) for each volunteer are shown in Tables 1 and 2, 
respectively. The percent change between kel and tl/2 values calcu-
lated before and after cimetidine administration revealed a large 
inter-subject variation. Kel changes ranged from -24% to +13.6% and 
tl/2 changes ranged from -11.9% to +31.7%. 
The mean (± standard deviation) elimination rate constant for 
piroxicam declined from 0.0149 ± 0.0036 hours"1 to 0.0139 ± 0.0035 
-1 
hours following the administration of cimetidine. The mean (+SD) 
half-life before and after cimetidine was 49.9 ± 15.5 hours and 53.4 
± 16.5 hours, respectively. These results were not statistically 
significant (F > 0.05) . The Type II error was estimated to be 24% 
for these two parameters. 
The calculated area under the piroxicam serum concentration-time 
curve (AUC) before and after cimetidine are summarized in Table 3. 
For all subjects but one the AUC was greater after cimetidine 
administration, resulting in a statistically significant 15.5% 
9 
(range: -2,41 to 29.5%) increase in AUC from 144.52 to 168.02 mg-
hours/L (p = 0.009). 
Coefficients of determination were calculated from the least 
square regression lines used to calculate the elimination rate 
constants. Their values ranged from 0.80 to 0.99 with a mean of 
0.90. 
Compliance assessed by interviews, capsule counts, and diary 
entries was 1001 in five volunteers, 98.2% in three volunteers, and 
96.4% in two volunteers. 
The following adverse reactions were reported by the volunteers 
during cimetidine administration: flatus (5), diarrhea (2), headache 
(2), nausea (1), anorexia (1), and fatigue (1). The number of 
volunteers who experienced the adverse reactions appears in paren-
theses. None of the volunteers experienced additional adverse 
reactions when piroxicam was added to cimetidine. 
10 
DISCUSSION 
The pharmacokinetic parameters of piroxicam obtained before the 
administration of cimetidine were compared to values reported in the 
literature in similar populations. Other studies have reported mean 
34-41 
half-lives ranging from 37.5 to 60.4 hours compared to the mean 
half-life of 49.8 hours in the present study. Mean areas under the 
piroxicam serum concentration-time curve from time zero to infinity 
after a 20 mg oral dose varied from 100.6 to 169 mg-hours/L compared 
34-41 
to the mean of 144.5 obtained in this study. Although statis-
tical analysis was not used in comparing these values, it appears 
that the pharmacokinetic values obtained from this study are within 
the range of those reported in other studies. 
Cimetidine decreases the elimination of a large number of drugs 
metabolized by hepatic mixed function oxidases. This effect is 
probably due to inhibition of cytochrome P-450 in hepatic micro-
somes.^ ^ Piroxicam is metabolized in the liver by hydroxylation 
42 
followed by glucuronldation. In this study, the administration of 
cimetidine did not significantly change the piroxicam elimination 
rate from the serum in the majority of subjects. 
It is well known that the clearance rate of drugs primarily 
eliminated by microsomal metabolism is highly variable among 
patients. One source of variability is the recent recognition of 
multiple forms of cytochrome P-450.®7 ^ These cytochrome P-450 
isoenzymes vary in their metabolizing activity for a given substrate 
and exhibit varying degrees of overlapping substrate activity. 
Recent studies with rat liver microsomes identified two different 
cytochrome P-450 isoenzymes capable of binding cimetidine: one with a 
high affinity binding site and one with a low affinity binding 
67 
site. Assuming similar findings in humans, it is possible that 
piroxicam is metabolized by the low affinity cytochrome P-450 isoen-
zyme, explaining the absence of effect of cimetidine on kel in the 
majority of our subjects. Since we did not measure the urinary 
metabolites of piroxicam we are unable to determine if there is any 
change in the pattern of metabolite formation when cimetidine is 
given with piroxicam. 
The lack of a statistically significant difference between the 
pre- and post-cimetidine elimination rate constants was probably not 
an artifact since the Type II error was within an acceptable range 
(i.e. 24%). Thus, the likelihood of missing an important effect on 
kel is unlikely. 
Although the elimination rate constants were not significantly 
different, the calculated AUCs were significantly increased after 
cimetidine administration. AUC is directly proportional to bioavail-
ability and dose, and is inversely related to elimination rate 
constant (kel) and apparent volume of distribution (Vd). Since the 
piroxicam dose given on both occasions was the same, the observed 
increase in AUC could be explained by an increase in the bioavail-
ability, a decrease in Vd or kel, or a combined effect of these 
factors. 
Cimetidine-induced alterations of gastric pH may increase 
bioavailability. According to the Henderson-Hasselbach equation, 
elevation of gastric pH by cimetidine would increase the Ionization 
of weak acids; therefore, dissolution would be enhanced. Assuming an 
accelerated dissolution of piroxicam, a weak acid, following cimeti-
dine administration, subsequent absorption of piroxicam from the 
intestine possibly could be increased. However, administration of 
35 
antacids does not modify the pharmacokinetics of piroxicam. 
A decrease in Vd possibly could be explained by tissue binding 
displacement. Displacement of drugs from tissue binding sites by 
cimetidine is possible since its steady-state volume of distribution 
71-73 
is 0.8 to 1.2 liter/kg, and a large fraction of the cimetidine 
74 
dose distributes into skeletal muscles. Because piroxicam has an 
36 
apparent Vd of 0.12 to 0.16 liter/kg, which is approximately the 
volume of the extracellular fluid compartment, it is unlikely that 
tissue binding displacement would be significant. 
Although the elimination rate constants before and after cimeti-
dine were not significantly different, there was a trend toward a 
decrease in kel after cimetidine administration. This may also 
contribute to the observed increase in AUC after cimetidine adminis-
tration. However, the statistically significant increase in AUC 
(mean: 15%) observed in this study is probably not clinically 
significant. 
When the plasma concentration-time profiles were examined, more 
than one peak of drug concentration was revealed. This may indicate 
enterohepatic recirculation of piroxicam as proposed by other 
Investigators 38iAO,41 
This study demonstrated that cimetidine administration slightly 
but significantly Increased the area under the piroxicam concentra-
tion versus time curve, in ten young and healthy males. Cimetidine 
administration did not affect the elimination rate constant or the 
13 
half-life of piroxicam in the same subjects. The results of this 
study suggest that cimetidine does not alter the elimination kinetics 
of a single dose of piroxicam in young healthy males. 
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TABLES 
TABLE 1 
ELIMINATION RATE CONSTANT (Kel) OP PIROXICAM 
BEFORE AND AFTER CIMETIDINE ADMINISTRATION 
SUBJECT Kel 













after cimetidine CHANGE 
(Hours ) % 
0.0150 - 2.6 
0.0184 - 4.2 
0.0154 -12.0 










0.0139 - 5.9 
0.0035 
p value = 0.135 
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TABLE 
HALF-LIFE (tl/2) OF PIROXICAM BEFORE AND 
AFTER CIMETIDINE ADMINISTRATION 
SUBJECT t 1/2 













after cimetidine CHANGE 
(HOURS) % 
46.2 + 2.7 
37.7 + 4.4 
45.0 +13.6 










53.4 + 7.8 
16.5 
p value = 0.106 
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TABLE 3 
AREA UNDER THE PIROXICAM SERUM CONCENTRATION VERSUS TIME CURVE (AUC) 
























































p value = 0.009 
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PATIENT CONSENT FORM 
DATE 
Study Title: The Effect of Cimetidine on Serum Concentrations of 
Piroxicam 
The purpose of this 3# week research study is to determine 
whether cimetidine (Tagamet ), a drug used in the management of 
peptic ulcer disease, causes an increase in the blood concentration 
of piroxicam. Piroxicam is a drug used to relieve pain and inflam-
mation associated with such disorders as rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis, etc. 
Prior to beginning the study, you will undergo a medical evalua-
tion to insure that you meet the requirements for this study and are 
not at unusual risk for serious toxicity if you participate. This 
evaluation will include a physical examination and medical and 
medication histories. In addition, approximately 1 tablespoonful of 
blood will be obtained by venipuncture (inserting a needle into a 
vein) and a urine sample will be collected in order to perform some 
laboratory studies. If found eligible to participate in this study, 
you will be scheduled to come to the hospital one morning to receive 
20 milligrams of piroxicam by mouth. Seven milliliters (about 
teaspoonful) of blood will be drawn before the piroxicam dose and 
then at regularly scheduled times over the next 96 hours, (4 days), 
A total of 18 blood samples will be obtained during this time 
(approximately 81 tablespoonfuls of blood). These blood samples will 
be obtained by either venipuncture (inserting a needle into a vein) 
or temporarily implanting a heparin lock (a needle which is flushed 
with an anticoagulant regularly) into a vein from which blood will be 
drawn. You will also be asked to collect all your urine for 7 days 
following the piroxicam administration. You will then begin taking 
cimetidine 300 milligrams four times a day for the next 14 days, to 
be taken by mouth, with each meal and at bedtime. After taking 
cimetidine for 7 days you will return to the hospital and once again 
take 20 mg. of piroxicam. Blood samples and urine will be collected 
in a manner identical to the procedure described above. During this 
3 week study the total amount of blood obtained will be approximately 
8 ounces (about 1 cup), 
You will be asked not to take any medications, other drugs, or 
alcohol while you are participating in this study and for 2 weeks 
before receiving the first dose of the piroxicam. If you use 
tobacco, are currently taking medications, or are allergic to 
aspirin, piroxicam, or cimetidine you should not participate In this 
study, 
The two medications used in this study are being used clinically 
and have been approved by the Food and Drug Administration for use in 
the United States. The most common side effects or discomforts 
associated with the use of piroxicam are abdominal pain, heartburn, 
nausea, vomiting and fluid retention. These are not usually serious 
and will usually resolve without treatment. Rare but more serious 
side effects include stomach ulcers, intestinal bleeding and 
decreased kidney function. These are very unlikely to occur follow-
ing single doses of piroxicam. Adverse reactions that may occur 
Patient Consent "Form 
The Effect of Cimetidine 
Page 2 32 
during cimetidine therapy include headaches, dizziness, rashes, 
drowsiness, transient increases in laboratory measures of liver 
function and kidney function, and reduction in sperm counts. These 
are usually not serious and resolve following discontinuation of the 
drug. A potentially serious but rare side effect of cimetidine is 
development of slow heart rate. 
Your participation in this study is completely voluntary. 
However, because of the pain, discomfort, amount of time involved, 
and inconveniences that you will endure because of participating in 
this study, you will be reimbursed up to $75.00 for satisfactorily 
completing all phases of this study. If, for some reason, you 
discontinue this study prematurely, you will be reimbursed according 
to the length of time you participate in this study. You may be 
withdrawn from the study at any time, either by your decision or your 
physician's decision without penalty or loss of benefits pertaining 
to future treatment. In addition, refusal to participate in this 
study will involve no penalty or loss of benefits. The data obtained 
from the study will be used for medical and scientific purposes, 
including publication. During the study, representatives of the Food 
and Drug Administration may review your medical records. All infor-
mation will remain strictly confidential. 
The laboratory tests are performed during this study as a 
precaution to decrease the possibility of injury. However, these 
precautions do not eliminate all possibilities of injury. In the 
event you sustain physical injury resulting from the research project 
in which you are participating, the University of Utah will provide 
you, without charge, emergency and temporary medical treatment not 
otherwise covered by insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting 
in the course and scope of their employment, the University may be 
liable, subject to limitations prescribed by law, for additional 
medical costs and other damages you sustain. If you believe that you 
have suffered a physical injury as a result of participation in this 
research program, please contact the Office of Research Administra-
tion, phone number: (801) 581-6903. 
Should you have further questions pertaining to the study, your 
rights as a participant in this study, or experience any problems 
during the study, please contact Dr. John R. Ward or Dr. Stephen 
Dahl, phone number: (801) 581-7724. 
I , agree to participate in this 
research study which is entitled "The Effect of Cimetidine on Serum 
Concentrations of Piroxicam". By signing this form, I also acknow-
ledge that I have had the opportunity to ask questions about the 
procedures, risks, and other items that are involved in this trial. 
PATIENT'S SIGNATURE DATE 
WITNESS'S SIGNATURE INVESTIGATOR'S SIGNATURE 
SCREENING VISIT 
THE EFFECT OF CIMETIDINE ON SERUM CONCENTRATIONS OF PIROXICAM 
SUBJECT INITIALS: / / / SUBJECT NO: / / / 
AGE: 
DATE OF EXAM: _ / _ / / 
M D Y 
Vital Signs, Height and Weight: 
TEMP: °F RR / tain PULSE _/mln 
B/P: / romHg 
syst diast 
HEIGHT : in ( cm) 
WEIGHT: lb ( kg) 
IBW (calculated): kg 
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SUBJECT INITIALS: / / / SUBJECT NO: I I I 
PHYSICAL EXAMINATION 
Normal Abnormal Describe 
1 2 Abnormality 
1. Head, Neck and Thyroid 














Physician's Signature Date 
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Drinker: \ N (if yes describe) 
MEDICATION HISTORY: 





SUBJECT INITIALS: / / / SUBJECT NO: _ / _ / _ / 
DATE: / / / 
M D Y 
iL. 
• INTENSITY RATING SCALE: 
1 = MILD - Awareness of  sign or symptom 
but easily tolerated 
2 = MODERATE - Discomfort  enough to cat 
interference  with usual 
activity 
3 - SEVERE - Incapacitating with inability 







1 = None 
2 = Discon-
tinued 














1 = Definitely 
Not 
2 = Prolmhly 
Not 
3 = Possibly 
4 = Probably 
5 = Definitely 
PATIENT OUTCOME 
TO DATE 
1 = Recovered -No 
Reiidual Effect* 
2 = Adverse Reaction 
Still Present -
No Treatment 
3 = Adverse Reaction 
Still Present -
Being Treated 
4 = Residual Effect*. 
Present -
No Treatment 
5 = Reiidual Effects 
Present -
Being Treated 
6 = Died (Give details 



















CIMETIDINE (TAGAMET®) ADMINISTRATION LOG: 
SUBJECT INITIALS: __/_/_/ SUBJECT NO: _/__/__/ 
DATE CIMETIDINE STARTED: 
























| g| j 
I!: ! i 
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PIROXICAM SAMPLE COLLECTION: 
SUBJECT INITIALS: _/_/__/ SUBJECT NO: __/__/_/ 
DATE: / / / 
M D Y 
Pre-Cimetidine: Post-Clmetidine: 
Piroxicam 20 mg taken at: (= TIME 0) 
Breakfast taken at: 
Blood Samples: 




















SUBJECT INITIALS: _/_/__/ SUBJECT NO: __/__/__/ 
Urine Samples: 











1) Ideal Body Weight 
Ideal Weight (kg) = 50kg + 2,3 kg/inch [Height(inches)-60] 
2) Half-life (tl/2) 
Tl/2 = 0.693 
kel 
3) Area under the serum concentration versus time curve (AUG); 
a) linear trapezoidal method: 
AUG. = C . + C (t - t .) 1 n-1 n n n—1 
b) logarithmic trapezoidal method: 
AUC •= (C , - C ) (t - t ) 
2 m-1 m m m-1 
In C , - In C m-1 m 
c) extrapolation: 
AUC„ = Cp Cp last measurable data point 3 x rx 
kel 
4) Type II error: 
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